Hyperpolarised 13C MRI: a new horizon for non-invasive diagnosis of aggressive breast cancer.
journal contributionposted on 17.01.2020 by Oshaani Abeyakoon, Arash Latifoltojar, Fiona Gong, Marianthi-Vasiliki Papoutsaki, Rafat Chowdhury, Matthias Glaser, Hassan Jeraj, Ramla Awais, Christopher Holt, Frazer Twyman, Erik Arstad, David G Gadian, David Atkinson, Arnaud Comment, James O'Callaghan, Lorna Smith, Teresita Beeston, Joey Clemente, Neill Patani, Rob Stein, Mariia Yuneva, Gyorgi Szabadkai, Steve Halligan, Shonit Punwani
Any type of content formally published in an academic journal, usually following a peer-review process.
Hyperpolarised 13C MRI (HP-MRI) is a novel imaging technique that allows real-time analysis of metabolic pathways in vivo.1 The technology to conduct HP-MRI in humans has recently become available and is starting to be clinically applied. As knowledge of molecular biology advances, it is increasingly apparent that cancer cell metabolism is related to disease outcomes, with lactate attracting specific attention. 2 Recent reviews of breast cancer screening programs have raised concerns and increased public awareness of over treatment. The scientific community needs to shift focus from improving cancer detection alone to pursuing novel methods of distinguishing aggressive breast cancers from those which will remain indolent. HP-MRI offers the opportunity to identify aggressive tumour phenotypes and help monitor/predict therapeutic response. Here we report one of the first cases of breast cancer imaged using HP-MRI alongside correlative conventional imaging, including breast MRI.